MedTrace Logo

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

NCT03602508 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5589

Last updated 2024-10-16

No results posted yet for this study

Summary

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.

This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Conditions

  • Overactive Bladder (OAB)

Interventions

DRUG

mirabegron

oral

DRUG

solifenacin

oral

DRUG

darifenacin

oral

DRUG

imidafenacin

oral

DRUG

tolterodine

oral

DRUG

oxybutynin

oral

DRUG

trospium

oral

DRUG

fesoterodine

oral

DRUG

propiverine

oral

Sponsors & Collaborators

  • Astellas Pharma Singapore Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Singapore Pte. Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-20
Primary Completion
2019-09-13
Completion
2019-09-13

Countries

  • Australia
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03602508 on ClinicalTrials.gov